JBS Science, sem byggir í Pennsylvaníu, sagði í dag að það hefði fengið 3 milljóna dala Bridge Award fyrir nýsköpunarrannsóknir í smáfyrirtækjum IIB frá National Cancer Institute. Fyrirtækið þróaði fyrstu fljótandi vefjasýnisvöruna, sem er þvag-DNA skimun fyrir snemma lifrarfrumukrabbameini (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of lifrarkrabbamein. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating æxli DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS sagðist hafa unnið með James Hamilton frá Johns Hopkins háskólalæknismiðstöðinni og Hie-Won Hann frá Thomas háskólasjúkrahúsinu til að efla þróun þvagprófs á lifrarkrabbameini.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
